Effects of Insulin on Hypotension and Sarcopenia

Diabetes Clinical Trial

Official title: Effects of Insulin on Hypotension and Sarcopenia

Status Withdrawn

Clinical Trial Summary

In this study investigator's aim to determine the impact of insulin therapy on hypotension and sarcopenia

Clinical Trial Description

Diabetes is common in the elderly. By the age of 70, approximately 25% of the population has diabetes and another 25% is at risk for diabetes. Elderly patients with diabetes are at increased risk for disability and reduction in their instrumental and basic activities of daily living. The prevalence of frailty is higher in people with diabetes that with age matched controls without diabetes. One of the major contributing factors to frailty is sarcopenia. Insulin is an important anabolic hormone that prevents protein breakdown and to a lesser extent stimulates protein synthesis. There is some evidence that the ability of insulin to stimulate anabolic processes may be reduced in diabetes. Insulin has cardiovascular properties, resulting in simultaneous adrenergic and vasodilatory responses that have opposing influences on blood pressure. Epidemiological studies have demonstrated that the use of insulin is a risk factor for syncope. The investigators will study 30 older adults age 65 and older with type 2 diabetes who have never taken insulin to manage their diabetes but now need insulin to manage their diabetes. Data will be compared pre insulin start and 3 and 6 months after starting insulin. ;

Related Conditions & MeSH terms

• Diabetes
• Hypotension
• Hypotension, Orthostatic
• Sarcopenia

• NCT number: NCT03248271
• Study type: Observational
• Source: University of British Columbia
• Status: Withdrawn
• Start date: October 1, 2017
• Completion date: January 10, 2023